Mizuho analyst Irina Koffler upgraded Pacira Biosciences (PCRX) to Neutral from Underperform and raised her price target for the shares to $38 from $29. The analyst says her sell thesis on the shares is longer valid due to an unexpected delay at competitor Heron Therapeutics (HRTX) and Pacira’s stronger guidance on recently acquired iovera. However, she still remains concerned about the longer-term outlook for the company.
https://thefly.com/landingPageNews.php?id=2903485
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.